Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-04-22

Clinical Trial Update: Belimumab Impacting Transplant Eligibility [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating belimumab and its impact on transplant eligibility in renal transplant rejection patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Belimumab (belimumab)

Snippet

Sponsor: E. Steve Woodle | Conditions: Renal Transplant Rejection | Phase 1, Phase 2 | Status: COMPLETED